Risk of Product Obsolescence Driven by New Technologies, New Products and the Emergence of Competitors
First written in FY2016. 12 of 14 entries say "Restated". Latest entry: FY2024-Q1.
The whole theme swung hardest in 2026: 28 of 57 companies on the "Worse" side.
65 other companies' latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the financial position, operating results or cash flows of the Group among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The Company explains that there have been no material changes in existing risks, including the risk of product obsolescence due to new technologies, new products and the emergence of competitors. - FY2022ReframedAnnual report
「In addition, sales of medical supplies in this business, including medical gloves, PCR detection reagents and antigen test kits, are subject to intense competition among manufacturers and trading companies of various sizes.」
In addition to the conventional competitive risks centered on product obsolescence, the scope has been expanded to include price and service competition involving medical supplies and GEO solutions. - FY2021-Q3RestatedAnnual report
「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new products and the emergence of competitors. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no new major risks that management recognizes could have a material impact on the financial condition, operating results or cash flows of the filing company, and no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new products and the emergence of competitors. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, no new business or other risks arose. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new products and the emergence of competitors. - FY2019RestatedAnnual report
「The development of new technologies beyond the Company’s expectations, adoption of new methods, emergence of new products or the rise of competitors could render the products handled by the Company obsolete or reduce their market value, potentially affecting the Company’s operating results.」
The Company continues to describe the risk of product obsolescence due to new technologies, new methods, new products and the emergence of competitors. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, no new business or other risks arose. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new methods, new products and the emergence of competitors. - FY2018RestatedAnnual report
「The development of new technologies beyond the Company’s expectations, adoption of new methods, emergence of new products or the rise of competitors could render the products handled by the Company obsolete or reduce their market value, potentially affecting the Company’s operating results.」
The Company continues to describe the risks of product obsolescence and declining market value due to new technologies, new methods, new products and the emergence of competitors. - FY2018-Q1RestatedAnnual report
「During the cumulative consolidated period for the first quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new methods, new products and the emergence of competitors. - FY2017RestatedAnnual report
「The development of new technologies beyond the Group’s expectations, adoption of new methods, emergence of new products or the rise of competitors could render products handled by the Group obsolete or reduce their market value, potentially affecting the Group’s operating results.」
The Company continues to describe the risk of product obsolescence due to new technologies, new methods, new products and the emergence of competitors. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter, no new business or other risks arose. In addition, there were no material changes in the business and other risks described in the securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new products and the emergence of competitors. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter, no new business or other risks arose. In addition, there were no material changes in the business and other risks described in the securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new products and the emergence of competitors. - FY2017-Q1RestatedAnnual report
「During the cumulative consolidated period for the first quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes have been reported regarding the risk of product obsolescence due to new technologies, new products and the emergence of competitors. - FY2016First statedAnnual report
「The development of new technologies beyond the Company’s expectations, adoption of new methods, emergence of new products or the rise of competitors could render the products handled by the Company obsolete or reduce their market value, potentially affecting the Company’s operating results.」
The Company identifies obsolescence and declining market value resulting from technological innovation, changes in methods, new products and the emergence of competitors in the medical imaging business as risks.